INTRODUCTION
Esophageal cancer is one of the most common gas trointestinal malignancies and is highly prevalent in Asia. Esophageal squamous cell carcinoma (ESCC) represents the most common histological type of esophageal cancer, accounting for more than 90% of all cases in Asian patients [1] . Although the 5year survival rate for patients with ESCC has improved in recent decades, the prognosis remains unfavorable due to the invasive nature of the disease and the frequency of late diagnosis [2] . An improved understanding of immunobiology has uncovered the interaction between programmed death ligand1 (PDL1) and programmed death 1 (PD1) as one of mechanisms by which cancer cells evade immune surveillance. PD1 is a negative costimulatory factor that inhibits T cell activation when activated by PDL1 or one of its other ligands [3, 4] , PDL1 is a cell surface glycoprotein that belongs to the B7 family and is expressed not only on normal cells, such as T cells, B cells, monocytes, macrophages, and dendritic cells, but also on cancer cells [47] . The PDL1/PD1 interaction has been found to be associated with poor prognosis and clinical outcomes in various cancers such as non small cell lung cancer, breast cancer, gastric cancer, soft tissue sarcomas and meningioma [8] ; however, its prognostic value is still controversial. Immune checkpointblocking agents directed at this interaction have been clinically successful and have been shown to produce a durable clinical response in esophageal cancer patients [9] . Considering the clinical importance of PDL1, there is great interest in understanding the mechanisms that regulate its expression. PDL1 upregulation has been reported in human papilloma virus (HPV)associated malignancies, including uterine, cervical, and head and neck cancers [1012] . PDL1 expression may be associated with HPV infection, which represents one of the potential causes of ESCC [13] . Furthermore, cMet, a receptor tyrosine kinase that is aberrantly activated in numerous human cancers [14] , has been shown to promote PDL1 overexpression in renal cell and pulmonary squamous cell carcinoma [15, 16] . However, a comprehensive analysis of the correlation between PDL1 and cMet expression in ESCC has not yet been reported.
In this study, we aimed to investigate the expression of PDL1 in ESCC and explore the correlation between PDL1 expression and cMet, as well as p16, a surrogate marker for HPV infection [17] . Additionally, we evaluated the potential for a prognostic role for PDL1, p16, and cMet expression in ESCC.
MATERIALS AND METHODS

Patients and samples
Patients with ESCC who underwent radical esopha gectomy with standard lymphadenectomy (two-field or threefield lymphadenectomy) as the initial definitive treatment in Seoul National University Hospital from December 2000 to April 2013 were eligible for this retrospective analysis. All tumor tissues were confirmed to be ESCC through hematoxylin and eosin staining after surgical resection. Tissue microarrays (TMAs; 2 mm in diameter) were constructed by collecting tissue cores from representative intratumoral areas from surgical specimens. The pathologic tumornodemetastasis (TNM) stage was characterized according to the 7 th American Joint Committee on Cancer Guidelines [18] .
Treatment strategies
Treatment decisions were made via a multidisciplinary teambased approach. All patients without clinical evidence of metastatic disease were treated with radial esophagectomy. The type of esophageal resection was dictated by the size, stage, and location of the primary tumor. According to the clinician's judgment, selec ted patients were offered neoadjuvant or adjuvant chemotherapy with or without radiation therapy. The chemotherapy regimen was fluoropyrimidine-/taxenebased and was selected based on the performance statuses, comorbidities, and toxicity profiles of indi vidual patients.
Immunohistochemistry
Immunohistochemistry (IHC) was performed using the Benchmark XT automated staining system (Ventana Medical Systems, Tucson, AZ, United States) to estimate the expression of PDL1, p16, and cMet. A rabbit antiPDL1 (E1L3N 
Outcome measurements
The primary objectives of this study were to evaluate PDL1 expression in ESCC and to evaluate the correlations between PDL1 expression and other clinicopathologic features, including p16 and cMet expression. The secondary objective was to assess the prognostic value of PDL1, p16, and cMet expression for overall survival (OS) and progressionfree survival (PFS). OS was defined as the time from the date of diagnosis until either death due to any cause or the last follow-up date. PFS was defined as the time from the first day of definitive treatment until locoregional/ distant relapse or progression, death, or last follow up. Locoregional relapse refers to regional lymph node metastasis or tumor recurrence at the primary site. OS of patients who received palliative chemotherapy and/ or radiotherapy (OSpall) was measured from the date of relapse or surgery (if R0 resection was not achieved) until either death due to any cause or the last follow up date.
Statistical analysis
Patients were divided into two groups by PDL1 status. Significant differences in clinicopathologic characteristics between the two groups were assessed using the MannWhitney test for continuous variables and the χ 2 (or Fisher's exact test, if appropriate) for categorical variables. Significant correlations between clinicopatholoic factors and PDL1positivity were assessed by logistic regression analysis. Survival analyses were performed using the KaplanMeier method and were compared using a logrank test. Univariate and multivariate analyses using the Cox proportional hazard regression model were applied to determine the hazard ratio (HR) for specific variables with respect to OS and PFS. For all statistical analyses, twosided P values < 0.05 were considered statistically significant. All statistical analyses were carried out using STATA version 12 (StataCorp LP, College Station, TX, United States).
RESULTS
Patient characteristics
A total of 200 ESCC patients were included in our analysis. The clinicopathologic characteristics of the patients are summarized in Table 1 . Most of the patients (94.0%) were males who ranged in age from 41 to 83 years (median age, 65 years). A majority of the patients were ex/currentsmokers (84.9%) or alcohol drinkers (84.3%). All patients underwent radical esophagectomy as an initial definitive treatment, and R0 resection was achieved in 176 patients (88.0%). Twenty patients (10.0%) received neoadjuvant chemotherapy prior to surgery, and 64 patients (32.0%) received adjuvant chemotherapy.
with scores of 1+, 2+, or 3+ were considered to be PDL1positive. cMet expression was analyzed by the membranous and/or cytoplasmic staining pattern and the positivity was evaluated by Hscore. The cMet staining intensity was scored as 0 (none or staining in less than 10% tumor cells), 1 (weak), 2 (moderate), or 3 (strong) based on membranous and/or cytoplas mic staining as previously reported [19, 20] ( Figure 1B ), and each score multiplied by the percentage of cells (0%100%). Therefore, Hscore was ranged from 0 to 300. The median value 50 of cMet Hscore among samples with positive cMet IHC staining was arbitrarily defined as the cutoff value for cMet positivity. Samples were considered positive for p16 staining if diffuse strong nuclear and cytoplasmic immunostaining was observed in more than 50% of the tumor cells ( Figure 1C ) [21] . All slides were blinded with respect to clinical characteristics and outcome and were reviewed and scored by two experienced pathologists (Kwon D 
Correlation of PD-L1 expression with p16 and c-Met expression in ESCC
IHC was performed to assess PDL1, p16, and cMet expression in surgical specimens collected from a total of 200 ESCC patients (Table 1 ). Tumor tissues from 67 patients (33.5%) were PDL1positive, and the remaining specimens (133 patients, 66.5%) were PDL1negative. PDL1positivity was not significantly correlated with any clinical characteristics, including age, sex, smoking/alcoholic history, stage, or differentiation (Table 1) . A total of 21 samples were positive for p16 expression (10.5%), 12 of which were PDL1negative and 9 of which were PDL1positive.
The cMet Hscores were ≥ 50 in 42 of 200 samples (21.0%). Of these cases, 21 were PDL1negative, and the remaining 21 were PDL1positive.
The factors associated with PDL1 expression were investigated by univariate and multivariate analyses using a logistic regression model (Table 2) . Most clinical characteristics, including age, sex, smoking/ alcoholic history, carcinoembryonic antigen (CEA) level, TNM stage and neoadjuvant chemotherapy were not significantly associated with PDL1 expression. Moderately or poorly differentiated ESCC tended to be PDL1positive compared to welldifferentiated ESCC in both univariate (P = 0.058) and multivariate analysis (P = 0.080). PDL1 expression was not significantly associated with p16 expression (P = 0.340), but elevated cMet expression (Hscore ≥ 50) was significantly associated with PD-L1-positivity compared to lower cMet expression (Hscore < 50) (OR = 2.34, 95%CI: 1.164.72, P = 0.017 in multivariate analysis).
Prognostic implications of PD-L1, p16, and c-Met expression for ESCC
In our cohort of ESCC patients, there was no significant difference in the OS (P = 0.656) according to PDL1 expression (Figure 2A ). Modifying the threshold for PDL1positivity by IHC score (e.g., 1+, 2+ or 3+) also did not yield a significant difference (data not shown). However, the locoregional relapse rate tended to increase (P = 0.134; Figure 2B ), and the distant metastasis rate was significantly increased in patients with PDL1positive ESCC compared to those with PD L1negative ESCC (HR = 1.72, 95%CI: 1.062.79, P = 0.028; Figure 2C ). To investigate the prognostic factors for OS in ESCC, univariate and multivariate Cox regression analyses were carried out (Table 3 ). There was no significant difference in OS according to c-Met expression (P = 0.601; Figure 3A ). However, there was a trend toward improved OS in patients with p16 positive ESCC compared to those with p16negative ESCC in univariate analysis (HR = 0.49; 95%CI: 0.241.01, P = 0.053; Figure 3B ) and multivariate analysis (HR = 0.51, 95%CI: 0.251.05, P = 0.069). This tendency became statistically significant in PD-L1-positive ESCC patients (HR = 0.23, 95%CI: 0.060.96, P = 0.043; Figure 3C ), but not in PDL1negative ESCC patients (P = 0.932; Figure 3D ). Interestingly, the OSpall was significantly better in patients with PDL1positive ESCC compared to those with PDL1 negatvie ESCC (HR = 0.59, 95%CI: 0.360.96, P = 0.034; Figure 4 ).
DISCUSSION
In this study, we report that approximately onethird of ESCC cases were positive for expression of PDL1, and that PDL1 expression was positively correlated with cMetpositivity. Although PDL1positivity appeared to have no prognostic value for OS, it was associated with increased rate of distant failure. Expression of p16, a marker for HPV infection, was not correlated with the PDL1 expression.
Because the PDL1/PD1 interaction has a negative regulatory function in T cell activation, cancer patients with elevated PDL1 expression often exhibit a poor prognosis and clinical outcomes [8] . With respect to ESCC, Ohigashi et al [22] analyzed data from 41 patients with ESCC and showed that PDL1 can serve as a prognostic biomarker for ESCC. Similarly, Chen et al [23] reported that PDL1 expression was significan tly associated with patient survival by analyzing 99 patients with ESCC. In contrast, we found no significant difference in survival of ESCC patients according to PDL1 expression. The discrepancies among these studies can be partially explained by variations in the antibodies used for detection, as well as differing IHC cutoff definitions for PDL1positivity. ESCC speci mens with any positive immunohistochemial staining using the rabbit antiPDL1 (E1L3N) XP ® mAb were considered positive in our analysis. However, Ohigashi et al [22] performed immunostaining with a mouse anti PDL1 immunoglobulin G1 mAb (MIH1) and considered specimens with ≥ 10% PDL1positive tumor cells to be positive. In contrast, Chen et al [23] used the Hscore method to assess PDL1 immunostaining with a rabbit antihuman PDL1 mAb (NBP103220). In addition to these variations in technique, differences in the multidisciplinary approach to treatment, such as use of palliative chemotherapy, radiotherapy, and supportive care might have also influenced OS. Furthermore, differences in tissue preparation and processing variability could have confounded results regarding the use of PDL1 IHC as a prognostic marker for ESCC. cMet is one of the most important cancer associated receptor tyrosine kinases and is activated through binding to its specific ligand, HGF [24] . cMet has been reported to be involved in the development of a number of human primary tumors, such as gastric, breast, colorectal, liver, and rectal cancers [25] . Activation of the receptor enhances oncogenesis through a wide range of mechanisms, including the promotion of tumor cell invasiveness, angiogenesis, and the epithelialtomesenchymal transition [24, 26] .
Based on its many roles in regulation of prooncogenic pathways, we hypothesized that cMet modulates PDL1 expression in ESCC. Consistent with this hypothesis, cMetinduced signaling has been reported to lead to PDL1 overexpression in renal cancer cells [15] . Our analysis demonstrated that cMet expression is significantly correlated with PD-L1-positivity in ESCC. However, in agreement with a previous report [27] , cMet overexpression had no prognostic value for OS [27] . Thus, the biological impact of the correlation between PDL1 and cMet expression should be further investigated in future studies.
HPV infection is one of the risk factors associated with esophageal cancer, oropharyngeal squamous cell carcinoma, and cervical cancer [13, 2830] . Previous reports have shown that HPVpositive tumors exhibit high PDL1 expression compared to HPVnegative tumors [1012] . With respect to ESCC, we did not observe any significant correlation between expression of PD-L1 and that of p16, a surrogate marker for HPV infection [17] . However, we did find that p16 expression has potential prognostic value for ESCC. This result was similar to that observed in patients with oropharyngeal squamous cell carcinoma [30, 31] . Interestingly, the prognostic value of p16 expression was more significant in patients with PDL1positive ESCC. There are several limitations that must be con sidered regarding the findings of this study. First, the retrospective design could bias the results. Second, there is no standard IHC threshold definition for PDL1, p16 and cMet positivity, and our definition was arbitrary. Therefore, one should be cautious when generalizing the results of our analysis. Third, we used p16 IHC as a surrogate marker instead of detecting HPV DNA to assess HPV infection. Fourth, although we identified a positive correlation between PDL1 and cMet expression, the biological meaning of the correlation was not investigated in this study.
Therefore, further followup studies including external validation are needed. Nevertheless, the present study represents the largest retrospective study to date with sufficient statistical power to assess PD-L1 expression and its prognostic implications in ESCC patients. Furthermore, the correlation between PDL1 and cMet expression in ESCC identified in this study is a novel finding.
In conclusion, approximately onethird of the ESCC patient samples analyzed were positive for PDL1 expression, and PDL1 expression was positively correlated with cMet expression. Although PDL1 positivity was not found to be associated with the prognosis of ESCC patients, it may play a critical role in distant metastasis and progression of ESCC. Because most cancerrelated deaths are associated with distant metastasis, our findings provide a rationale for immunotherapy targeting PDL1 for ESCC.
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